The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Kura Oncology, Inc. COM 50127T109   7,338,421 1,111,882 SH   SOLE   1,111,882 0 0
Lyell Immunopharma, Inc. COM 55083R104   8,612,303 16,007,999 SH   SOLE   16,007,999 0 0
Maze Therapeutics Inc COM 578784100   23,252,228 2,111,919 SH   SOLE   2,111,919 0 0
Pharvaris N.V. COM N69605108   69,246,122 4,410,581 SH   SOLE   4,410,581 0 0
Relay Therapeutics Inc. COM 75943R102   2,620,000 1,000,000 SH   SOLE   1,000,000 0 0